All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

R. Nelson, David; N. Cooper, James; P. Lalezari, Jacob; Lawitz, Eric; J. Pockros, Paul; Gitlin, Norman; F. Freilich, Bradley; H. Younes, Ziad; Harlan, William; Ghalib, Reem; Oguchi, Godson; J. Thuluvath, Paul; Ortiz‐Lasanta, Grisell; Rabinovitz, Mordechai; Bernstein, David; Bennett, Michael; Hawkins, Trevor; Ravendhran, Natarajan; M. Sheikh, Aasim; Varunok, Peter; V. Kowdley, Kris; Hennicken, Delphine; McPhee, Fiona; Rana, Khurram; A. Hughes, Eric; behalf of the ALLY‐3 Study Team, on

doi:10.1002/hep.27726

Public

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

Shared by NobleBlocks on Mar 10, 2015 • 12:00 AM UTC

Authors:

David R. Nelson

James N. Cooper

Jacob P. Lalezari

Abstract

Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all‐oral regimens requiring 24‐week treatment and the addition of ribavirin (RBV). This phase III study (ALLY‐3; ClinicalTrials.gov: NCT02032901) evaluated the 12‐week regimen of...

Discussions